Therapeutic effect of arachidonic acid (ARA) on Schistosomiasis japonicum in mice
TANG Xian-shi, ZHAO Song, XIONG Chun-rong, JIANG Tian-tian, TONG De-sheng, YANG Kun
Key Laboratory of National Health and Family Planning Commission on Parasitic Disease Control and Prevention,Jiangsu Provincial Key Laboratory on Parasite and Vector Control Technology, Jiangsu Institute of Parasitic Diseases,Wuxi 214064,China
Abstract：To reveal ARA’s effects against Schistosoma japonicum in BALB/c and C57BL/6j mouse hosts, we randomly divided mice infected with S. japonicum cercariae into three groups: an administration group, solvent group and untreated group. Mice in the administration group were given ARA solution at a dose of 300 mg/kg for 2 consecutive days or 7 consecutive days at different time points, whereas mice in the solvent group were given only corn oil. Mice in each group were dissected on the 42nd day after infection, and adult worms and liver eggs were collected and counted to calculate the worm and egg reduction rates. ARA effectively suppressed adult Schistosoma japonicum (28-35 days) in mice at the dose of 300 mg/kg, with a worm reduction rate above 40% and a liver egg reduction rate of more than 70%; the differences between the administration and the solvent groups were statistically significant. However, ARA at the same concentration had no obvious effects against S. japonicum during the schistosomulum stage (1-28 days) in mice. The results revealed that S. japonicum adult worms are sensitive to ARA; therefore, ARA has the potential to be used in the chemical treatment of S. japonicum in the future.
[1] Brash AR.Arachidonic acid as a bioactive molecule[J]. J Clin Invest, 2001,107(11):1339-1345. DOI: 10.1172/JCI13210 [2] Zhou L, Nilsson A.Sources of eicosanoid precursor fatty acid pools in tissues[J]. J Lipid Res, 2001,42(10):1521-42. [3] Nelson GJ, Kelley DS, Emken EA, et al.A human dietary arachidonic acid supplementation study conducted in a metabolic research unit: rationale and design[J]. Lipids,1997,32(4):415-420. DOI: 10.1007/s11745-997-0054-8 [4] El Ridi RA, Tallima HA.Novel therapeutic and prevention approaches for schistosomiasis: review.[J]. J Adv Res, 2013,4(5):467-478. DOI: 10.1016/j.jare.2012.05.002 [5] Steinmann PJ, Keiser R, Bos M,et al.Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk[J]. Lancet Infect Dis, 2006,6(7):411-425. DOI: 10.1016/S1473-3099(06)70521-7 [6] Gryseels B, Polman K, Clerinx J, et al.Human schistosomiasis[J]. Lancet,2006, 368(9541):1106-1118. DOI: 10.1016/S0140-6736(06)69440-3 [7] Botros SS, Bennett JL.Praziquantel resistance[J]. Expert Opin. Drug Discov, 2007, 2(s1):S35-40. DOI: 10.1517/17460441.2.S1.S35 [8] 翟自立, 肖树华, 陈名刚, 等.一个令人担忧的问题:血吸虫对吡喹酮产生抗性[J].中国血吸虫病防治杂志, 1999,11(2):121-124. [9] Gnanasekar M, Salunkhe AM, Mallia AK, et al.2009. Praziquantel affects the regulatory myosin light chain of Schistosoma mansoni[J]. Antimicrob Agents Chemother, 2009,53(3):1054-1060. DOI: 10.1128/AAC.01222-08 [10] Pica-Mattoccia L, Valle C, Basso A, et al.Cytochalasin D abolishes the schistosomicidal activity of praziquantel[J]. Exp Parasitol, 2007,115(4):344-351. DOI: 10.1016/j.exppara.2006.09.017 [11] Tallima H, El Ridi R.Praziquantel binds Schistosoma mansoni adult worm actin[J]. Int J Antimicrob Agents, 2007,29(5):570-5. DOI: 10.1016/j.ijantimicag.2006.12.018 [12] El Ridi R, Aboueldahab M, Tallima H, et al.In vitro and in vivo activities of arachidonic acid against Schistosoma mansoni and Schistosoma haematobium[J]. Antimicrob Agents Chemother, 2010,54(8):3383-3389. DOI: 10.1128/AAC.00173-10 [13] El Ridi R, Tallima H, Salah M, et al.Efficacy and mechanism of action of arachidonic acid in the treatment of hamsters infected with Schistosoma mansoni or Schistosoma haematobium[J]. Int J Antimicrob Agents, 2012, 39(3):232-239. DOI: 10.1016/j.ijantimicag.2011.08.019 [14] Robinson BS, Hii CS, Poulos A, et al.Activation of neutral sphingomyelinase in human neutrophils by polyunsaturated fatty acids[J]. Immunology,1997,91(2):274-280. DOI: 10.1046/j.1365-2567.1997.d01-2227.x [15] Tallima H, Al-Halbosiy MF, El Ridi R.Enzymatic activity and immunolocalization of Schistosoma mansoni and Schistosoma haematobium neutral sphingomyelinase[J]. Mol Biochem Parasitol, 2011,178(1/2):23-28. DOI: 10.1016/j.molbiopara.2011.04.003 [16] El Ridi R, Tallima H.Equilibrium in lung schistosomula sphingomyelin breakdown and biosynthesis allows very small molecules, but not antibody, to access proteins at the host-parasite interface[J]. J Parasitol, 2006,92(4):730-737. DOI: 10.1645/GE-745R1.1 [17] El Ridi R, Tallima H, Migliardo F.Biochemical and biophysical methodologies open the road for effective schistosomiasis therapy and vaccination[J]. Biochim Biophys Acta Gen Subj, 2017,1861(1 Pt B):3613-3620. DOI: 10.1016/j.bbagen.2016.03.036 [18] Goni FM, Alonso A.Sphingomyelinases: enzymology and membrane activity[J]. FEBS Lett, 2002,531(1):38-46. DOI: 10.1016/s0014-5793(02)03482-8 [19] Tallima H, Salah M, El-Ridi R.In vitro and in vivo effects of unsaturated fatty acids on Schistosoma mansoni and S. haematobium lung-stage larvae[J]. J Parasitol, 2005,91(5):1094-1102. DOI: 10.1645/GE-514R.1 [20] El Ridi R, Mohamed SH, Tallima H.Incubation of Schistosoma mansoni lung stage schistosomula in corn oil exposes their surface membrane antigenic specifificities[J]. J Parasitol, 2003,89(5):1064-1067. DOI: 10.1645/GE-3122RN [21] Selim S, El Sagheer O, El Amir A, et al.Efficacy and safety of arachidonic acid for treatment of Schistosoma mansoni-infected children in Menoufiya, Egypt[J]. Am J Trop Med Hyg, 2014,91(5):973-981. DOI: 10.4269/ajtmh.14-0328
2021, Vol. 37 
